MCID: ART140
MIFTS: 52

Arteries, Anomalies of

Categories: Cardiovascular diseases

Aliases & Classifications for Arteries, Anomalies of

MalaCards integrated aliases for Arteries, Anomalies of:

Name: Arteries, Anomalies of 56
Artery Disease 12 15
Arteriopathic Disease 71

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
arteries, anomalies of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050828
OMIM 56 108000
MedGen 41 C1876179
SNOMED-CT via HPO 68 263681008 49601007
UMLS 71 C0852949

Summaries for Arteries, Anomalies of

Disease Ontology : 12 A vascular disease that is located in an artery.

MalaCards based summary : Arteries, Anomalies of, also known as artery disease, is related to carotid artery disease and pulmonary artery disease. An important gene associated with Arteries, Anomalies of is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Nicardipine and Esmolol have been mentioned in the context of this disorder. Affiliated tissues include an artery, heart and endothelial, and related phenotype is abnormality of the cardiovascular system.

More information from OMIM: 108000

Related Diseases for Arteries, Anomalies of

Diseases related to Arteries, Anomalies of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1163)
# Related Disease Score Top Affiliating Genes
1 carotid artery disease 35.1 REN MIR126 ACE
2 pulmonary artery disease 34.9 SERPINA3 MIR126 ACE
3 lipoprotein quantitative trait locus 34.6 REN MIR21 MIR199A1 MIR146A MIR126 ACE
4 coronary heart disease 1 34.2 MIR221 MIR17 MIR155 MIR126 ACE
5 vascular disease 33.7 REN MIR221 MIR21 MIR199A1 MIR146A MIR126
6 myocardial infarction 33.5 SERPINA3 REN MIR499A MIR423 MIR34A MIR221
7 arteriosclerosis 33.5 MIR21 MIR155 MIR133A1 MIR126 ACE
8 cardiovascular system disease 33.3 SERPINA3 REN MIR590 MIR499A MIR423 MIR34A
9 heart disease 33.3 REN MIR499A MIR423 MIR210 MIR21 MIR199A1
10 aortic disease 33.2 SERPINA3 REN MIR21 MIR199A1 MIR17 MIR126
11 intermediate coronary syndrome 32.6 MIR423 MIR126 ACE
12 lipid metabolism disorder 32.6 MIR33A MIR21 MIR126 H2AC18 ACE
13 fibromuscular dysplasia 32.6 REN ACE
14 limb ischemia 32.4 MIR210 MIR21 ACE
15 cerebrovascular disease 32.4 SERPINA3 REN MIR221 MIR21 MIR199A1 ACE
16 acute myocardial infarction 32.2 SERPINA3 REN MIR499A MIR423 MIR34A MIR21
17 diabetes mellitus 32.2 REN MIR34A MIR17 MIR155 MIR146A MIR126
18 atrial fibrillation 32.1 REN MIR21 MIR199A1 MIR146A MIR133A1 MIR126
19 heart valve disease 32.0 SERPINA3 REN MIR499A MIR423 MIR21 MIR199A1
20 diabetes mellitus, noninsulin-dependent 32.0 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR17
21 aortic aneurysm, familial abdominal, 1 32.0 SERPINA3 MIR199A1 ACE
22 pulmonary disease, chronic obstructive 31.9 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR126
23 mitral valve insufficiency 31.9 REN MIR423 ACE
24 hypertension, essential 31.8 SERPINA3 REN MIR590 MIR423 MIR33A MIR24-1
25 non-alcoholic fatty liver disease 31.8 MIR34A MIR33A MIR21 MIR199A1 MIR17 MIR155
26 aortic valve disease 2 31.8 SERPINA3 REN MIR590 MIR423 MIR34A MIR21
27 body mass index quantitative trait locus 11 31.7 SERPINA3 REN MIR423 MIR34A MIR221 MIR21
28 microvascular complications of diabetes 3 31.6 REN MIR21 ACE
29 peripheral nervous system disease 31.6 SERPINA3 REN MIR21 MIR146A MIR126 H2AC18
30 systemic lupus erythematosus 31.6 MIR423 MIR210 MIR21 MIR155 MIR146A H2AC18
31 heart septal defect 31.5 MIR499A MIR423 MIR199A1 MIR17 H2AC18
32 microvascular complications of diabetes 5 31.5 MIR21 MIR126 H2AC18 ACE
33 mitral valve stenosis 31.5 SERPINA3 REN ACE
34 mitral valve disease 31.5 SERPINA3 REN MIR423 ACE
35 psoriasis 31.4 MIR21 MIR17 MIR155 MIR146A CCR6 ACE
36 periodontitis 31.4 SERPINA3 MIR21 MIR146A
37 diabetes mellitus, type i 31.3 REN MIR499A MIR210 MIR21 H2AC18 CCR6
38 mental depression 31.3 SERPINA3 MIR24-1 H2AC18
39 retinal vascular disease 31.2 REN MIR21 MIR199A1 MIR126 H2AC18 ACE
40 sexual disorder 31.2 SERPINA3 H2AC18 ACE
41 dilated cardiomyopathy 31.2 SERPINA3 REN MIR499A MIR199A1 MIR146A ACE
42 systemic scleroderma 31.2 MIR21 H2AC18 CCR6 ACE
43 generalized atherosclerosis 31.2 REN ACE
44 respiratory failure 31.1 SERPINA3 REN H2AC18 CCR6 ACE
45 connective tissue disease 31.1 SERPINA3 MIR590 MIR423 MIR34A MIR24-1 MIR221
46 orthostatic intolerance 31.1 REN MIR423 ACE
47 lung cancer 31.1 SERPINA3 MIR590 MIR499A MIR423 MIR34A MIR33A
48 aortic valve disease 1 31.0 REN MIR21 MIR199A1 MIR17 MIR126 ACE
49 substance abuse 31.0 SERPINA3 MIR199A1 H2AC18 CCR6
50 renal cell carcinoma, nonpapillary 31.0 MIR423 MIR34A MIR221 MIR210 MIR21 MIR199A1

Graphical network of the top 20 diseases related to Arteries, Anomalies of:



Diseases related to Arteries, Anomalies of

Symptoms & Phenotypes for Arteries, Anomalies of

Human phenotypes related to Arteries, Anomalies of:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 31 HP:0001626

Symptoms via clinical synopsis from OMIM:

56
Vascular:
abnormal radial, ulnar, or interosseous artery

Clinical features from OMIM:

108000

Drugs & Therapeutics for Arteries, Anomalies of

Drugs for Arteries, Anomalies of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 825)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
2
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
5
Fenoldopam Approved Phase 4 67227-57-0, 67227-56-9 3341
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
12
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
13
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
14
Chlorthalidone Approved Phase 4 77-36-1 2732
15
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
17
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
18
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
19
Eplerenone Approved Phase 4 107724-20-9 150310 443872
20
Dobutamine Approved Phase 4 34368-04-2 36811
21
Ticlopidine Approved Phase 4 55142-85-3 5472
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
24
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
25
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
26
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
27
Zinc Approved, Investigational Phase 4 7440-66-6 32051
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
30
Probucol Approved, Investigational Phase 4 23288-49-5 4912
31
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
32
Remifentanil Approved Phase 4 132875-61-7 60815
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
35
Saxagliptin Approved Phase 4 361442-04-8 11243969
36
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
37
Digoxin Approved Phase 4 20830-75-5 30322 2724385
38
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
39
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
40
Histamine Approved, Investigational Phase 4 51-45-6 774
41
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
42
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
43
Cosyntropin Approved Phase 4 16960-16-0 16129617
44
Etomidate Approved Phase 4 33125-97-2 36339 667484
45
Magnesium citrate Approved Phase 4 3344-18-1
46
Magnesium oxide Approved Phase 4 1309-48-4 14792
47
Citalopram Approved Phase 4 59729-33-8 2771
48
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
49
Linagliptin Approved Phase 4 668270-12-0 10096344
50
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824

Interventional clinical trials:

(show top 50) (show all 6010)
# Name Status NCT ID Phase Drugs
1 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
2 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
3 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
4 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
5 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
6 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
7 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
8 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
9 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
10 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
11 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
12 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
13 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
14 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
15 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C
16 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
17 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
18 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
19 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
20 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
21 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
22 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
23 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
24 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
25 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
26 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
27 The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions) Unknown status NCT01375465 Phase 4
28 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
29 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
30 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
31 Individual-Patient-Data Pooled-Analysis of Diagnostic Accuracy of Noninvasive Fractional Flow Reserve From Anatomic CT Angiography Unknown status NCT01747317 Phase 4
32 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
33 Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents Unknown status NCT01781715 Phase 4
34 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
35 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
36 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
37 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
38 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
39 Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) Unknown status NCT01278186 Phase 4
40 2-phased Randomized Comparison Between PromusTMElementTM Versus Xience PRIME® Stent Unknown status NCT01581515 Phase 4
41 Use of Hypertonic Versus Isotonic Solutions in Off Pump Coronary Artery Bypass Graft Surgery Targeting the Left Marginal Branch Unknown status NCT01463917 Phase 4 Hypertonic solution;Isotonic
42 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
43 Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial Unknown status NCT01807078 Phase 4 Ezetimibe
44 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
45 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
46 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
47 Effect of Statins on the Progression of the Intima-media Thickness of the Radial Artery After Radial Angioplasty Unknown status NCT00952770 Phase 4
48 Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression Unknown status NCT01086020 Phase 4 atorvastatin;atorvastatin plus ezetimibe
49 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
50 Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography Unknown status NCT01024179 Phase 4

Search NIH Clinical Center for Arteries, Anomalies of

Genetic Tests for Arteries, Anomalies of

Anatomical Context for Arteries, Anomalies of

The Foundational Model of Anatomy Ontology organs/tissues related to Arteries, Anomalies of:

19
An Artery

MalaCards organs/tissues related to Arteries, Anomalies of:

40
Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Arteries, Anomalies of

Articles related to Arteries, Anomalies of:

(show top 50) (show all 30005)
# Title Authors PMID Year
1
Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis. 61
31950864 2020
2
Validity of epicardial fat volume as biomarker of coronary artery disease in symptomatic individuals: Results from the ALTER-BIO registry. 61
32331905 2020
3
ADTRP regulates TFPI expression via transcription factor POU1F1 involved in coronary artery disease. 61
32445923 2020
4
Complete revascularization for patients with multivessel coronary artery disease and ST-segment elevation myocardial infarction after the COMPLETE trial: A meta-analysis of randomized controlled trials. 61
32577495 2020
5
Analysis of two single-nucleotide polymorphisms (rs2241766 and rs1501299) of the adiponectin gene in patients with coronary artery disease and coronary slow flow. 61
32153153 2020
6
Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study. 61
32223966 2020
7
Genetics of type 2 diabetes and coronary artery disease and their associations with twelve cardiometabolic traits in the United Arab Emirates population. 61
32360841 2020
8
Circulating interleukins, coronary artery disease, ischemic stroke and atrial fibrillation: Connecting the dots between inflammation and cardiovascular disease. 61
32330473 2020
9
Decision tree-based diagnosis of coronary artery disease: CART model. 61
32179311 2020
10
Guanxin V for coronary artery disease: A retrospective study. 61
32485568 2020
11
Prognostic Value of Abnormal Ankle-Brachial Index in Patients With Coronary Artery Disease: A Meta-Analysis. 61
32166959 2020
12
Ultrasound Measurement of Carotid Intima-Media Thickness and Plaques in Predicting Coronary Artery Disease. 61
32386846 2020
13
Optimal Medical Treatment vs. Invasive Approach in Patients with Significantly Obstructive Coronary Artery Disease and Ischemia. 61
32327292 2020
14
Clinical impact of complex percutaneous coronary intervention in patients with coronary artery disease. 61
31350706 2020
15
Long-Term Clinical Effects of Carotid Intraplaque Neovascularization in Patients with Coronary Artery Disease. 61
32524790 2020
16
Evaluation of intracranial and extracranial atherosclerotic lesions in patients with symptomatic coronary artery disease. 61
32284016 2020
17
Colchicine prevents stroke in patients with coronary artery disease - a trial sequential analysis. 61
32202673 2020
18
Concomitant chronic venous insufficiency in patients with peripheral artery disease: insights from MR angiography. 61
32100090 2020
19
Endothelial function in response to exercise in the cold in patients with coronary artery disease. 61
32227393 2020
20
Reconciling the evidence on the treatment of left main coronary artery disease. 61
32067835 2020
21
Early diastolic strain rate by two-dimensional speckle tracking echocardiography is a predictor of coronary artery disease and cardiovascular events in stable angina pectoris. 61
32405734 2020
22
Accuracy of a novel stress echocardiography pattern for myocardial bridging in patients with angina and no obstructive coronary artery disease - A retrospective and prospective cohort study. 61
32145938 2020
23
Safety and Feasibility of Simultaneous Transcarotid Revascularization With Flow Reversal and Coronary Artery Bypass Grafting for Concomitant Carotid Artery Stenosis and Coronary Artery Disease. 61
32319354 2020
24
Low blood pressure and cardiovascular events in diabetic patients with coronary artery disease after revascularization: the CREDO-Kyoto registry cohort-1. 61
32015482 2020
25
Impact of machine-learning CT-derived fractional flow reserve for the diagnosis and management of coronary artery disease in the randomized CRESCENT trials. 61
32166492 2020
26
Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey. 61
32474205 2020
27
Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry). 61
32418717 2020
28
Serum concentration of dihomo-γ-linolenic acid is associated with cognitive function and mild cognitive impairment in coronary artery disease patients. 61
31767440 2020
29
Pericardial Fat Enhancement: New Computed Tomography Biomarker Influences the Relationship Between Pericardial Fat and Coronary Artery Disease. 61
31913256 2020
30
Association of Circulating Hepatocyte Growth Factor and Risk of Incident Peripheral Artery Disease: The Multi-Ethnic Study of Atherosclerosis. 61
32202143 2020
31
The Effect of an Empowerment Program on the Perceived Risk and Physical Health of Patients with Coronary Artery Disease: Erratum. 61
32541626 2020
32
Association of Plasma Marker of Oxidized Lipid with Histologic Plaque Instability in Patients with Peripheral Artery Disease. 61
31706994 2020
33
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. 61
31549153 2020
34
Low-dose dynamic myocardial perfusion imaging by CZT-SPECT in the identification of obstructive coronary artery disease. 61
31848673 2020
35
Prognostic Value of Subclinical Coronary Artery Disease in Atrial Fibrillation Patients Identified by Coronary Computed Tomography Angiography. 61
32345472 2020
36
Re: Correlation between Internal Pudendal Artery Stenosis and Erectile Dysfunction in Patients with Suspected Coronary Artery Disease. 61
32293950 2020
37
Association of combined genetic variations in SOD3, GPX3, PON1, and GSTT1 with hypertension and severity of coronary artery disease. 61
32034489 2020
38
Characteristics of high-cost inpatients with peripheral artery disease. 61
31980246 2020
39
Use of statins in patients with peripheral artery disease. 61
31307839 2020
40
Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. 61
32498804 2020
41
Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. 61
32500165 2020
42
Endothelial glycocalyx and severity and vulnerability of coronary plaque in patients with coronary artery disease. 61
32361241 2020
43
Comanagement of Risk Factors in Patients With Coronary Artery Disease: Insights From the APPEAR Study. 61
32441197 2020
44
Weather-related subjective well-being in patients with coronary artery disease. 61
32494961 2020
45
Serum apolipoprotein A-I concentration differs in coronary and peripheral artery disease. 61
32491935 2020
46
Impact of coronary bypass or stenting on mortality and myocardial infarction in stable coronary artery disease. 61
32037130 2020
47
OBSTRUCTIVE coronary artery disease with a coronary artery calcium score of 0: A case report. 61
32506571 2020
48
Fractional flow reserve in patients with coronary artery disease undergoing TAVI: a prospective analysis. 61
31679046 2020
49
Association between perivascular inflammation and downstream myocardial perfusion in patients with suspected coronary artery disease. 61
32091086 2020
50
PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. 61
32577988 2020

Variations for Arteries, Anomalies of

Expression for Arteries, Anomalies of

Search GEO for disease gene expression data for Arteries, Anomalies of.

Pathways for Arteries, Anomalies of

Pathways related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR423 MIR34A MIR221 MIR210 MIR21 MIR199A1

GO Terms for Arteries, Anomalies of

Cellular components related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 SERPINA3 REN MIR590 MIR423 MIR24-1 MIR221
2 extracellular vesicle GO:1903561 9.43 MIR34A MIR24-1 MIR221 MIR21 MIR17 MIR126

Biological processes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.07 MIR34A MIR21 MIR155 MIR146A MIR133A1
2 negative regulation of gene expression GO:0010629 10.01 MIR33A MIR21 MIR17 MIR155 MIR146A ACE
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 MIR24-1 MIR221 MIR21 MIR126
4 positive regulation of protein kinase B signaling GO:0051897 9.94 MIR221 MIR21 MIR199A1 MIR126
5 positive regulation of angiogenesis GO:0045766 9.93 MIR210 MIR21 MIR199A1 MIR126
6 negative regulation of angiogenesis GO:0016525 9.91 MIR34A MIR24-1 MIR21 MIR146A
7 cholesterol homeostasis GO:0042632 9.87 MIR590 MIR34A MIR155
8 positive regulation of inflammatory response GO:0050729 9.87 MIR21 MIR155 MIR126
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.85 MIR221 MIR21 MIR133A1
10 negative regulation of inflammatory response GO:0050728 9.85 MIR590 MIR221 MIR155 MIR146A MIR126
11 cellular response to hypoxia GO:0071456 9.83 MIR34A MIR17 MIR155 MIR146A MIR126
12 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.81 MIR221 MIR199A1 MIR155 MIR146A
13 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR499A MIR221 MIR21 MIR17
14 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.79 MIR590 MIR21 MIR146A
15 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.79 MIR221 MIR155 MIR146A
16 positive regulation of blood vessel endothelial cell migration GO:0043536 9.78 MIR499A MIR221 MIR210 MIR126
17 negative regulation of sprouting angiogenesis GO:1903671 9.77 MIR34A MIR221 MIR17
18 negative regulation of vascular endothelial cell proliferation GO:1905563 9.77 MIR34A MIR24-1 MIR126
19 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.76 MIR499A MIR221 MIR21
20 positive regulation of vascular endothelial cell proliferation GO:1905564 9.75 MIR499A MIR21 MIR126
21 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.74 MIR21 MIR146A MIR126
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.73 MIR17 MIR155 MIR133A1
23 positive regulation of connective tissue replacement GO:1905205 9.72 MIR34A MIR199A1 MIR155
24 cell growth involved in cardiac muscle cell development GO:0061049 9.7 MIR24-1 MIR199A1
25 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.7 MIR24-1 MIR155
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.7 MIR199A1 MIR17 MIR155
27 amyloid-beta metabolic process GO:0050435 9.69 REN ACE
28 negative regulation of matrix metallopeptidase secretion GO:1904465 9.69 MIR199A1 MIR146A
29 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.68 MIR155 MIR146A
30 angiotensin maturation GO:0002003 9.68 REN ACE
31 negative regulation of cell adhesion molecule production GO:0060354 9.68 MIR221 MIR155
32 negative regulation of interleukin-8 production GO:0032717 9.67 MIR155 MIR146A
33 positive regulation of metalloendopeptidase activity GO:1904685 9.67 MIR21 MIR17
34 negative regulation by host of viral genome replication GO:0044828 9.66 MIR221 MIR155
35 negative regulation of myoblast proliferation GO:2000818 9.65 MIR499A MIR133A1
36 negative regulation of vascular wound healing GO:0061044 9.65 MIR34A MIR155
37 negative regulation of regulatory T cell differentiation GO:0045590 9.65 MIR21 MIR155
38 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.64 MIR221 MIR21
39 negative regulation of interleukin-21 production GO:0032705 9.63 MIR221 MIR21
40 positive regulation of cardiac muscle tissue regeneration GO:1905180 9.62 MIR590 MIR199A1
41 negative regulation of vascular endothelial growth factor production GO:1904046 9.62 MIR34A MIR199A1 MIR17 MIR146A
42 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR221 MIR155 MIR146A
43 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.56 MIR199A1 MIR17 MIR155 MIR133A1
44 miRNA mediated inhibition of translation GO:0035278 9.56 MIR590 MIR499A MIR221 MIR210 MIR21 MIR17
45 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.55 MIR590 MIR24-1 MIR21 MIR199A1 MIR133A1
46 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR210 MIR21 MIR17
47 gene silencing by miRNA GO:0035195 9.5 MIR590 MIR499A MIR423 MIR34A MIR33A MIR24-1

Molecular functions related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR590 MIR499A MIR423 MIR34A MIR33A MIR24-1

Sources for Arteries, Anomalies of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....